Global Medical Affairs Program | Amicus Therapeutics
Independent Medical EducationInvestigator-Initiated Studies


Independent Medical Education Program Grants

Accredited Medical Education Program Grants (U.S.)

Amicus Therapeutics supports programs and activities that foster excellence in patient care and provide valuable scientific, medical, and educational information to the medical and scientific communities. Grant funding for an accredited Continuing Medical Education (CME) program (i.e., ACCME, AMA, AAFP, ADA, or AOA) or continuing education for other allied health professions (e.g., nurses, pharmacists), from U.S.-based continuing education entities (e.g., academic institutions, education program vendors) will be considered. Since available grant funding is limited, selection priority is given to exceptional high quality, impactful educational activities (Moore’s Outcome Level 4 or higher) which serve to close gaps in health care provider (HCP) knowledge, skills, and professional performance used to provide services to patients, the public, or the profession. Amicus Therapeutics will not influence the content nor have control over those educational programs funded through Global Medical Affairs as independent medical education grants. An assessment plan of participant outcomes is a requirement for funding.

Non-Accredited Medical Education Program Grants

Amicus Therapeutics applies the same standards of independence to non-accredited continuing education (CE) grants with respect to content, influence, faculty selection, educational methods, materials, venues and attendees as it does to accredited CE grants. Examples of non-certified CE educational programs that Amicus Therapeutics can potentially support include, but are not limited to, the following:

  • Lectures or other educational activities
  • Managed care-sponsored educational activities
  • Grants to support healthcare-related public policy initiatives
  • Disease state and treatment education and awareness

Overview

  • Amicus Therapeutics is compliant with federal and state laws, as well as guidelines that govern such activities. Amicus Therapeutics commercial staff, including field staff, are not involved in decisions to fund IME programs.
  • Responsibility and control over the selection, content, faculty, educational methods, materials, and venue for an independent medical education event belongs solely to the organizers of the event in accordance with the accredited provider’s guidelines.
  • Amicus Therapeutics will not provide any advice or guidance to the accredited independent medical education provider (including, if requested) regarding program content or faculty for any Independent Medical Education program.
  • Amicus Therapeutics requires that a fully-executed Letter of Agreement (LOA), in the form provided by Amicus Therapeutics, be signed by the requesting Continuing Education Provider and Amicus Therapeutics Global Medical Affairs Independent Medical Education prior to the commencement of the Continuing Education program. Continuing education programs that have commenced in the past will not be approved nor funded by Amicus Therapeutics.
  • For those funding requests approved by Amicus Therapeutics, the IME funding recipient is required to confirm the completion of the activity and to provide documentation of how the funds were used within 90 days after the completion of the independent medical education activity. Reconciliation documentation should be uploaded to the grant application through the Amicus IME Grant Portal.
  • Funds provided by Amicus Therapeutics in support of an IME program and not spent in the execution of the program must be returned to Amicus Therapeutics.

Please note that Amicus Therapeutics will not provide educational grant funding for the following:

  • Individuals
  • Requests for payments to Individuals
  • Fellowships
  • Overhead Expenses
  • General Operating Expenses
  • Entertainment Expenses
  • Awards / Travel Awards
  • Costs of travel, lodging, or other personal expenses of non-faculty individuals attending IME, either directly to the individuals participating in the event or indirectly to the event’s provider.
  • Funding used to compensate participants for time spent at the IME event.
  • Debarred institutions or groups, including organizations or their employees on probation with the ACCME or other organizations, or on the OIG exclusion list; as well as faculty debarred from a federal healthcare program or on the OIG exclusion list.

Therapeutic/Disease State Areas of Interest

Amicus will consider funding certified educational grants for programs that address the following rare disease states:

  • Fabry Disease – IME grants with limited funding requests of up to $20,000 are currently being considered.

Certified CME funding requests are accepted for review on an ongoing basis and can be submitted at any time. Requests must be received no later than 90 days before the activity start date. Under no circumstances will CME funding requests be considered for programs that have taken place or started in the past.

Amicus Therapeutics, Inc., reserves the right to modify, revise or delete therapeutic areas of interest, and other terms and conditions of its CME funding program, at any time and without notice.

Request for Education

Requests for Education (RFE) may be published by Amicus periodically in therapeutic or disease state areas of interest based on educational gaps that are identified. To view RFEs currently posted please click HERE.

Grant Submission Process

Submit an application through our secure online portal, where you can track the status of your request and communicate with Amicus. The application captures the following information:

  • Unmet needs or educational gap assessment
  • Educational objectives
  • Program details:
    • Program title, date(s), and location(s)
    • Description of the proposed activity
    • Identification of the target audience and projected number of attendees.
    • Name of accrediting body and accredited provider, including type and number of medical education credits offered for the proposed activity (program must be accredited).
    • If applicable, identification of co-requesting organization(s), medical education partner(s), and/or logistical partner, including contact information for these organizations.
    • Whether or not the requestor is seeking co-funding support from other companies or entities.
    • Amount of funding requested from Amicus Therapeutics
  • Signed and dated by authorized representative
  • Proposed agenda (draft acceptable)
  • Proposed program outcomes assessment (e.g., pre- and post-test scores for the participants, participant survey with respect to the quality and / or utility of the educational program).
  • Full, itemized program budget (must use Amicus budget spreadsheet)
  • If applicable, a copy of the organization’s non-profit determination letter from the IRS.
  • Current IRS W-9 form or equivalent foreign documentation (must be signed and dated within the last 12 months).

If you are applying for the first time, Register Here. To continue an online application, or to check on the status of an application, Login Here. If you have additional questions, email us at GMA_IME@amicusrx.com.

Non-accredited Medical Education

Amicus funds unaccredited activities aimed at educating health care professionals, researchers, scientists, or patients, such as health-related public conferences, symposia, or community awareness campaigns where the program includes topics relating to disease management, therapy options and treatment.

If you are applying for the first time, Register Here. To continue an online application, or to check on the status of an application, Login Here. If you have additional questions, email us at GMA_IME@amicusrx.com.

Notification of Decision

The online portal allows you to track the progression of your grant request, and communicate with Amicus:

  • A confirmation email with an identification number is sent to the Requestor immediately following a submission
  • Requests for additional information are managed directly through the online portal
  • Once the review process is complete, an email notification with the decision is sent to the Requester
  • If grant request is approved, a Letter of Agreement will be sent to the Requester. Amicus Therapeutics requires that its form of agreement is fully executed prior to the start date of the program, content development or activity

Reconciliation

  • A completed reconciled budget form must be uploaded onto the approved grant via the online portal within ninety (90) days of the program end date
  • If the completed reconciled budget, or any other requested documentation are not received within the specified timeframes, the recipient will be precluded from receiving additional education funding
  • All unused funds must be returned to Amicus
  • The provision of outcome data (e.g., number of participants, participant areas of specialty, pre- and post-test scores, participant surveys) that measures effectiveness, value, benefit, or impact of a completed (live and/or enduring) IME program or event is required as a condition of funding

MED-AS-NN-1900001


Investigator-Initiated Studies

At Amicus Therapeutics (Amicus), we are committed to providing rigorous, groundbreaking science with real impact for people living with rare metabolic diseases. Investigator Initiated Studies (IIS) play an important role in advancing science by addressing the unmet research needs or areas of interest surrounding Amicus’ medical and scientific interests.

Amicus has a competitive research grant review process with specific requirements that must be met in-order for your application to be evaluated. IIS proposal applications are reviewed based on scientific merit, alignment with areas of interest, budget availability, and other considerations. 

Amicus provides support for independent research on a topic that is scientifically sound and within the published areas of research interest (see below). It is expected that results from IIS projects be communicated in scientific forums and/or published in in peer-reviewed journals.

We welcome the scientific and academic research communities to submit high-quality IIS proposals through our research application portal. New applications are accepted continuously throughout the year.

Suitable Types of IIS Proposals:

Non-clinical (ie, laboratory or animal studies), Clinical, Observational, Epidemiological, and Outcomes studies will be considered.

2020 Schedule for IIS Proposal Application Submission and Review:

You may submit your IIS proposal application at any time. Amicus reviews IIS proposals on a monthly basis.

Amicus IIS Areas of Interest*:

At this time, Amicus is accepting IIS proposal applications for Fabry disease in the following areas of interest presented below:

2020 IIS Areas of Interest:

  • Explore the role of tissue distribution and penetration and the relationship to treatment response and outcomes in Fabry patients with various manifestations (e.g. ophthalmologic, cardiovascular, neurologic)
  • Address predictive and prognostic biomarker discovery and validation, biomarker panels or novel combinations of biomarkers for informing early treatment, disease monitoring and organ specific treatment monitoring in Fabry disease
  • Explore the cellular and clinical effect of lysosomal dysfunction, inflammatory pathways or immunologic response on the pathophysiology of Fabry disease
  • Clinically address Fabry disease in female patients and address challenges of genotype/phenotype differences, responses to therapy, early treatment and access to care
  • Explore the pathophysiology and treatment management of pain and GI symptoms in Fabry disease
  • Address the incidence and prevalence and management of psychological or psychosocial manifestations in patients and families with Fabry disease

Amicus reserves the right to modify, revise or delete the AIs and other terms and conditions of its IIS program at any time without notice.

Concept Application

The IIS submission process is facilitated through a user-friendly online portal. The process begins with submission of a Concept Application. Review the application carefully and ensure you have completed all the requested information.  Please also include a copy of your signed and dated CV, key budget information/spreadsheet, and all supporting documents with your application.

Amicus strives to provide a response to your application within 30 days of scheduled review date. Submission of a proposal is not a guarantee of approval of that application.

NOTICE: Overhead on direct study costs is not to exceed 30% (this cannot be negotiated). 

Protocol Application

Once your IIS Concept Application has been approved; you will be notified of the decision and begin drafting the study protocol. To facilitate this process and ensure all necessary information is reflected in the protocol, we have provided an outline for both non-clinical and clinical studies as a guide that may be adapted as needed. Please see Resources section for protocol outline templates.

Once you have completed drafting your protocol, you may log back into the IIS portal and upload your protocol, budget spreadsheet template, and other supporting documents. Amicus strives to provide a response to your protocol within 30 days of the scheduled review date.

New Users REGISTER on IIS Portal – to begin the Concept Application submission process.

Returning Users GO to IIS PORTAL – to track the status of your application

Study Completion:

Upon completion of the IIS project, Amicus will complete a brief study close out process including budget reconciliation.

All unused funds must be returned to Amicus.

Thank you for your interest in the Amicus Therapeutics, Global Medical Affairs Investigator-Initiated Studies. Please email the Investigator Initiated Studies Administrator at Investigator-InitiatedProgram@amicusrx.com with additional questions.

MED-AS-NN-1900001
Last Review Date: 07/02/2020